A Study of E7386 in Combination With Other Anticancer Drug in Participants With Solid Tumor
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the safety and tolerability and to determine
the recommended Phase 2 dose (RP2D) of E7386 in combination with other anticancer drug(s).